Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

I
PII-171
IDENTIFY BIOPREDICTIVE DISSOLUTION FOR PREDICTING IN VIVO PERFORMANCE OF A BCS II DRUG PRODUCT UNDER FED CONDITION

Favorite
PII-079
IDENTIFYING EPIGENTIC INFLUENCES ON DRUG METABOLISM: MULTI-OMIC ANALYSES IN AFRICAN AMERICAN HEPATOCYTES

Favorite
PII-056
IMMUNOGENICITY AND SBMCA CHANGE IN THE COMPARISON OF TALQUETAMAB RECOMMENDED PHASE 2 DOSES

Favorite
PII-119
IMPACT OF CRUSHING OR GRINDING ON THE RELATIVE BIOAVAILABILITY OF THE VENETOCLAX TABLETS.

Favorite
PT-017
IMPACT OF CYP2D6 INHIBITORS ON PAIN CONTROL BY THE OPIOIDS

Favorite
PII-120
IMPACT OF MODERATE OR SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SOTORASIB AND ITS METABOLITES

Favorite
PII-121
IMPLEMENTATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING IN TRANSLATION AND DOSE SELECTION FOR FIRST-IN-HUMAN PHASE 1/2 CLINICAL STUDY OF NTLA-2002 IN THE TREATMENT OF HEREDITARY ANGIOEDEMA

Favorite
LB-016
IMPROVED NONCOMPARTMENTAL HALF-LIFE ESTIMATION WITH TOBIT REGRESSION.

Favorite
PII-172
IN SILICO PREDICTION OF ION CHANNEL EFFECTS OF METHADONE LEADING TO QT INTERVAL PROLONGATION.

Favorite
PII-080
IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM

Favorite
PII-122
INCREASED DOSE CORRECTED AUC FOLLOWING SLOW SUBCUTANEOUS, INTRAMUSCULAR AND ORAL VERSUS INTRAVENOUS BOLUS HUMAN DRUG DOSING AND ITS POTENTIAL FOR INCREASED DOSE CORRECTED PHARMACODYNAMIC EFFECTS.

Favorite
PT-027
INHIBITION OF TACROLIMUS METABOLISM BY CANNABIDIOL AND ITS METABOLITES IN VITRO.

Favorite
PT-005
INTEGRATED GENOMICS AND TRANSCRIPTOMICS ANALYSES USING HAPMAP CELL LINES REVEAL NOVEL MODULATORS OF CELLULAR RESPONSE TO CYCLOPHOSPHAMIDE.

Favorite
PII-057
INTEGRATED PHARMACOKINETIC (PK)/PHARMACODYNAMIC MODELING OF PK, SAFETY, AND EFFICACY DATA TO SUPPORT DOSE OPTIMIZATION OF BMS-986158, A BROMODOMAIN AND EXTRA-TERMINAL INHIBITOR (BETI), IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF).

Favorite
E-001
INVESTIGATION OF THE RELATIONSHIP BETWEEN LEPR GENOTYPE-LEPTIN-GUT MICROBIOTA COMPOSITION IN HEALTHY NON-OBESE KOREAN ADULTS.

Favorite